The Fda May Be In Hot Water Again
Just as the Food & Drug Administration is beginning to recover from the generic-drug scandals of 1988, the agency may be heading for another disgrace. A federal grand jury in Baltimore is investigating charges that FDA officials passed confidential information about coming drug approvals to brokerage firms in return for cash. Approval for a major drug often sends the stock of its maker soaring. An FDA spokesman admits that several employees have been subpoenaed but says that the agency has no evidence of wrongdoing.
To continue reading this article you must be a Bloomberg Professional Service Subscriber.
If you believe that you may have received this message in error please let us know.
- The U.S. Drops Out of the Top 10 in Innovation Ranking
- Here’s What Trump’s Tariffs on U.S. Imports Are Doing to Markets
- Musk's New Pay Deal Could Make Him the World's Richest Man—If Tesla Succeeds
- Trump's Tariffs on Solar Mark Biggest Blow to Renewables Yet
- This Rare Bear Who Called the Crash Warns Housing Is Too Hot Again